Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Using MRI to Diagnose Pancreatic Masses

Official title: Experimental and Clinical Study of Three-dimensional Magnetic Resonance Elastography to Evaluate Pancreatic Cancer and Interstitial Fibrosis

Run by Shengjing Hospital · NCT06526442 · Data updated 2026-11-12

This study is testing if a special MRI technique can help doctors better understand pancreatic cancer by measuring the stiffness of tumors to improve treatment decisions for patients.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment200 (estimated)
SponsorShengjing Hospital
Academic / other
Locations1 site (Shenyang, Liaoning)
StatusRecruiting
StartedOctober 9, 2020
Main results expectedAugust 1, 2026
Study endsJune 1, 2027
Registry record updatedFebruary 13, 2026
Trial IDNCT06526442 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 and older with confirmed pancreatic ductal adenocarcinoma and no history of other malignancies.

Probably not a fit

Patients with tumors smaller than 1.0 cm or those who have undergone preoperative biliary drainage may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to utilize high order three-dimensional magnetic resonance elastography (3D-MRE) to non-invasively measure the stiffness of pancreatic lesions, particularly pancreatic ductal adenocarcinoma (PDAC). By assessing the mechanical properties of the extracellular matrix surrounding PDAC, the study seeks to identify prognostic factors that could aid in risk stratification and treatment decisions. The research focuses on patients with definitive histologic evidence of PDAC and aims to correlate MRE imaging biomarkers with patient outcomes. The goal is to enhance the understanding of tumor biology and improve clinical management of pancreatic cancer.

Why it matters

Potential benefit: If successful, this approach could lead to better prognostic predictions and more tailored treatment options for patients with pancreatic cancer.

How similar studies have gone: While the application of MRE imaging biomarkers in predicting PDAC prognosis is novel, similar imaging techniques have shown promise in other cancer types.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. granting of written informed consent
2. age ≥18 years
3. no history of extrapancreatic malignancy
4. no preoperative biliary drainage
5. definitive histologic evidence of PDAC in excisional biopsy
6. with no less than three months of postoperative mortality or six months of follow- up

Exclusion Criteria:

1. inability to re-review of tissue specimens
2. unacceptable estimates of MRE parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and MRE hardware disconnection
3. tumor diameters \<1.0 cm
4. withdrawal/dropout during follow-up

Where it's running

  • Shengjing hospital of china medical university
    Shenyang, Liaoning, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.